AR044264A1 - Una forma de dosificacion que contiene pantoprazol como ingrediente activo - Google Patents

Una forma de dosificacion que contiene pantoprazol como ingrediente activo

Info

Publication number
AR044264A1
AR044264A1 ARP040101558A ARP040101558A AR044264A1 AR 044264 A1 AR044264 A1 AR 044264A1 AR P040101558 A ARP040101558 A AR P040101558A AR P040101558 A ARP040101558 A AR P040101558A AR 044264 A1 AR044264 A1 AR 044264A1
Authority
AR
Argentina
Prior art keywords
dosage form
pantoprazole magnesium
tablet
pellet
form according
Prior art date
Application number
ARP040101558A
Other languages
English (en)
Inventor
Dietrich Rango Dr
Anstett Isabel Dr
Schiller Marc Dr
Hartmut Ney
Schafer-Preuss Sabine Dr
Hartmann Manfred Dr
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33436112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044264(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of AR044264A1 publication Critical patent/AR044264A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formas de dosificación para la administración oral de la sal de magnesio de pantoprazol. Reivindicación 1: Una forma de dosificación para la administración oral de la sal de magnesio de pantoprazol, caracterizada porque comprende una cantidad terapéuticamente efectiva de la sal de magnesio de pantoprazol conjuntamente con excipientes farmacéuticamente aceptables. Reivindicación 2: Una forma de dosificación de acuerdo con la reivindicación 1, caracterizada porque es una forma de dosificación sólida en forma de tableta o pella. Reivindicación 3: Una forma de dosificación de acuerdo con la reivindicación 1, caracterizada porque es una forma de dosificación de liberación retardada que comprende una capa entérica soluble en condiciones neutras o alcalinas y al menos una capa intermedia (capa de subrecubrimiento). Reivindicación 5: Una forma de dosificación de acuerdo con la reivindicación 1, caracterizada porque es un medicamento oralmente administrable en la forma de pella o tableta que es resistente a jugo gástrico, y donde cada pella o tableta consiste de un núcleo en el cual el compuesto activo o su sal tolerada fisiológicamente se encuentra mezclado con un ligante, relleno y, opcionalmente, un miembro seleccionado del grupo formado por otro agente auxiliar para la formación de tabletas y un compuesto inorgánico básico tolerado fisiológicamente; una capa intermedia inerte soluble en agua que rodea el núcleo y una capa exterior resistente a jugo gástrico, donde el compuesto activo es pantoprazol magnesio dihidrato, el ligante es polivinilpirrolidona y/o hidroxipropilmetilcelulosa y, opcionalmente, el relleno es manitol. Reivindicación 28: Un método para la profilaxis o el tratamiento de una condición clínica en un mamífero, tal como un humano, para la cual está indicada un inhibidor de bomba protónica, método caracterizado porque comprende la administración de una cantidad terapéuticamente efectiva de pantoprazol magnesio en una forma de dosificación de acuerdo con cualquiera de las reivindicaciones 1 a 27. Reivindicación 29: Un método de tratamiento de acuerdo con la reivindicación 28, caracterizado porque la condición clínica se selecciona del grupo formado por úlcera gástrica benigna, enfermedad de reflujo gastro-esofágico, síndrome de Zollinger-Ellison, úlcera duodenal, úlcera duodenal asociada con Helicobacter pylori, profilaxis de úlcera gástrica o duodenal asociado con NSAID en pacientes con un riesgo aumentado de complicación gastroduodenal que requieran un tratamiento continuo con NSAID y una terapia de combinación con antibióticos en la erradicación de Helicobacter pylori.
ARP040101558A 2003-05-08 2004-05-07 Una forma de dosificacion que contiene pantoprazol como ingrediente activo AR044264A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010328 2003-05-08
EP04001754 2004-01-28

Publications (1)

Publication Number Publication Date
AR044264A1 true AR044264A1 (es) 2005-09-07

Family

ID=33436112

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101558A AR044264A1 (es) 2003-05-08 2004-05-07 Una forma de dosificacion que contiene pantoprazol como ingrediente activo

Country Status (27)

Country Link
US (2) US20060240100A1 (es)
EP (2) EP2316454B9 (es)
JP (2) JP4878284B2 (es)
KR (2) KR20110104124A (es)
AR (1) AR044264A1 (es)
AU (2) AU2004237363B2 (es)
BR (2) BRPI0410044B8 (es)
CA (1) CA2489140C (es)
CL (1) CL2004000983A1 (es)
CY (2) CY1113128T1 (es)
DK (2) DK1624869T3 (es)
EA (2) EA016824B1 (es)
ES (2) ES2396197T3 (es)
HK (1) HK1090546A1 (es)
HR (2) HRP20120754T1 (es)
IL (2) IL171365A (es)
MX (1) MXPA05000411A (es)
NO (1) NO337921B1 (es)
NZ (1) NZ543181A (es)
PE (1) PE20050199A1 (es)
PL (2) PL1624869T3 (es)
PT (2) PT1624869E (es)
RS (1) RS53443B (es)
SI (2) SI2316454T1 (es)
TW (1) TW200509992A (es)
WO (1) WO2004098594A2 (es)
ZA (1) ZA200508202B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
RS52233B (en) 2004-05-07 2012-10-31 Nycomed Gmbh THE PHARMACEUTICAL DOSAGE FORM CONTAINING GRANULES AND ITS PRODUCTION PROCEDURE
CA2608444A1 (en) * 2005-05-13 2007-03-15 Combino Pharm, S.L. Formulations containing pantoprazole free acid and its salts
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
BR112013000978A2 (pt) * 2010-07-22 2017-07-11 Lupin Ltd composição de tablete de unidade múltipla
KR101787481B1 (ko) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐
ITMI20111168A1 (it) * 2011-06-27 2012-12-28 Professional Dietetics Srl Composizioni farmaceutiche comprendenti idrossipropilmetilcellulosa e/o acido ialuronico e loro uso
WO2014016754A2 (en) * 2012-07-26 2014-01-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
IN201611034271A (de) * 2016-10-06 2018-04-13 Delayed Release Pharmaceutical Composition Of Pantoprazole And Process For Preparation Thereof
WO2023214016A1 (en) * 2022-05-06 2023-11-09 Evonik Operations Gmbh Dosage form with drug release at ph 3 to 6 using double coating system with at least one release acceleration agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
IL85472A (en) 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
DE3901151A1 (de) 1989-01-17 1990-07-19 Hoechst Ag Stabile pharmazeutische zubereitungen von thienoimidazol-derivaten und deren orale anwendung als magensaeuresekretionshemmer
US5183662A (en) 1990-08-30 1993-02-02 Senju Pharmaceutical Co., Ltd. Controlled drug release composition
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE157864T1 (de) * 1991-12-18 1997-09-15 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
EP0695123A4 (en) * 1993-04-27 1996-09-11 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING GASTRICAL FAULTS USING OPTICALLY PURE PANTOPRAZOLS
DK0723436T3 (da) 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
JP3249914B2 (ja) 1996-06-04 2002-01-28 清水食品株式会社 成型用焼結金型およびその形成方法
US6072024A (en) 1997-03-21 2000-06-06 Mitsui Chemicals, Inc. Production process of cross-linked polyaspartic acid resin
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
ATE260090T1 (de) 1997-12-08 2004-03-15 Altana Pharma Ag Neue suppositoriumsform mit säureempfindliche wirkstoffe
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
CU23051A3 (es) * 1998-05-15 2005-06-24 Warner Lambert Co Composiciones solidas que contienen derivados de acido gamma-aminobutirico y procesos para prepararlas.
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
JP3274416B2 (ja) * 1998-05-29 2002-04-15 佐藤製薬株式会社 口腔内崩壊性粒状製剤
ES2262335T3 (es) 1998-08-12 2006-11-16 Altana Pharma Ag Forma de administracion oral para piridin-2-ilmetilsulfinil-1h-bencimidazoles.
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
YU86001A (sh) 1999-06-07 2004-07-15 Altana Pharma Ag. Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
WO2002045694A1 (en) 2000-12-07 2002-06-13 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
WO2002045692A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
RS52233B (en) 2004-05-07 2012-10-31 Nycomed Gmbh THE PHARMACEUTICAL DOSAGE FORM CONTAINING GRANULES AND ITS PRODUCTION PROCEDURE
JP4563077B2 (ja) 2004-05-28 2010-10-13 株式会社ロッテ キャンディ及びその製造方法

Also Published As

Publication number Publication date
AU2004237363A1 (en) 2004-11-18
RS53443B (en) 2014-12-31
EP1624869B1 (en) 2012-07-04
JP4878284B2 (ja) 2012-02-15
IL171365A (en) 2014-08-31
EP1624869A2 (en) 2006-02-15
CY1113462T1 (el) 2016-06-22
NO337921B1 (no) 2016-07-11
BR122016006880B1 (pt) 2020-11-10
NZ543181A (en) 2009-10-30
EP2316454A1 (en) 2011-05-04
PL1624869T3 (pl) 2012-11-30
JP2011126912A (ja) 2011-06-30
DK2316454T3 (da) 2013-01-21
HRP20120754T1 (hr) 2012-11-30
EP2316454B9 (en) 2013-01-02
IL229510A (en) 2016-09-29
BRPI0410044B8 (pt) 2021-05-25
KR101237742B1 (ko) 2013-02-26
EP2316454B1 (en) 2012-09-26
NO20055631L (no) 2005-11-29
BRPI0410044A (pt) 2006-04-25
KR20110104124A (ko) 2011-09-21
JP5162689B2 (ja) 2013-03-13
CL2004000983A1 (es) 2005-03-04
IL229510A0 (en) 2013-12-31
US20060240100A1 (en) 2006-10-26
CY1113128T1 (el) 2016-04-13
HRP20121005T1 (hr) 2013-01-31
US8703192B2 (en) 2014-04-22
MXPA05000411A (es) 2005-03-23
WO2004098594A3 (en) 2004-12-09
PT2316454E (pt) 2012-12-06
TW200509992A (en) 2005-03-16
SI2316454T1 (sl) 2013-01-31
ES2396197T3 (es) 2013-02-19
CA2489140C (en) 2006-10-17
PL2316454T3 (pl) 2013-03-29
CA2489140A1 (en) 2004-11-18
WO2004098594A2 (en) 2004-11-18
EA200501697A1 (ru) 2006-06-30
RS20050818A (en) 2008-04-04
KR20060010774A (ko) 2006-02-02
EA027734B1 (ru) 2017-08-31
AU2004237363B2 (en) 2009-12-10
JP2006525286A (ja) 2006-11-09
AU2010200905A1 (en) 2010-04-01
EA016824B1 (ru) 2012-07-30
ES2390342T3 (es) 2012-11-12
ZA200508202B (en) 2006-12-27
US20090208571A1 (en) 2009-08-20
SI1624869T1 (sl) 2012-10-30
AU2010200905B2 (en) 2012-04-05
PT1624869E (pt) 2012-09-18
PE20050199A1 (es) 2005-03-26
DK1624869T3 (da) 2012-10-01
HK1090546A1 (en) 2006-12-29
EA201101119A1 (ru) 2011-12-30
BRPI0410044B1 (pt) 2019-05-07
BR122016006880B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
AR044264A1 (es) Una forma de dosificacion que contiene pantoprazol como ingrediente activo
RU2340358C2 (ru) Композиция, ингибирующая секрецию кислоты в желудке
AR044265A1 (es) Una forma de dosificacion que contiene (s) - pantoprazol como ingrediente activo
FI2498756T4 (fi) Neratinibimaleaatin tablettiformulaatiot
RU2008121767A (ru) Пероральная фармацевтическая лекарственная форма, содержащая в качестве активных ингредиентов ингибитор протонного насоса совместно с ацетилсалициловой кислотой
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
WO2003039519A3 (es) Forma de dosificación de liberación controlada dual
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
CA2301378A1 (en) Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
IL167591A (en) Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent
JP2002525266A5 (es)
KR20130029758A (ko) 불쾌한 맛을 갖는 약물을 함유하는 필름 제제
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
RU2001107149A (ru) Тауролидин и/или таурултам против инфекционной язвенной болезни или инфекционного гастрита
JP2005510485A5 (es)
JP2019508464A (ja) クロピドグレル及びアスピリンを含む複合製剤
JPH04230330A (ja) 非ステロイド系抗炎症薬によつて起こる胃腸症候の緩和のための薬剤配合物と緩和法
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
Robinson pH, healing and symptom relief with rabeprazole treatment in acid‐related disorders
WO2005065664A8 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
CA2740974A1 (en) Dosage forms for the rapid and sustained elevation of gastric ph
Bown An overview of the pharmacology, efficacy, safety and cost‐effectiveness of lansoprazole
RU2005122465A (ru) (-)-энантиомер тенатопразола и его применение в терапии
ES2466441T3 (es) Composiciones farmacéuticas que comprenden fármaco antiinflamatorio no esteroideo, acetaminofén e inhibidor de la bomba de protones
JP5303605B2 (ja) サリチル酸類含有経口組成物

Legal Events

Date Code Title Description
FC Refusal